Advances in fetal therapy
Article first published online: 24 JAN 2011
2010 Royal College of Obstetricians and Gynaecologists
The Obstetrician & Gynaecologist
Volume 12, Issue 2, pages 94–102, April 2010
How to Cite
Morris, R. K., Chan, B. C. and Kilby, M. D. (2010), Advances in fetal therapy. The Obstetrician & Gynaecologist, 12: 94–102. doi: 10.1576/toag.220.127.116.11574
- Issue published online: 24 JAN 2011
- Article first published online: 24 JAN 2011
- congenital diaphragmatic hernia;
- fetal alloimmune thrombocytopenia;
- gene therapy;
- lower urinary tract obstruction;
- stem cell transplantation;
- twin-to-twin transfusion syndrome
- •Fetal medicine is a rapidly developing subspecialty.
- •The mainstay of treatment for fetal alloimmune thrombocytopenia remains maternal immunoglobulin therapy.
- •Stem cell transplantation and gene therapy have advanced over the last decade but must still be considered experimental.
- •Laser coagulation is the best treatment for all stages of twin-to-twin transfusion syndrome presenting before 26 weeks of gestation.
- •Fetoscopic endoluminal tracheal occlusion appears to improve prognosis in severe congenital diaphragmatic hernia.
- •To gain an overview of the recent developments in fetal therapy.
- •To understand the benefits and risks of different methods of fetal therapy.
- •To appreciate the importance of high-quality research in fetal medicine.
- •With the option of fetal therapy, the value and implications of prenatal diagnosis have to be reviewed.
- •The acceptability of fetal therapy to parents and to society should be investigated.
- •The consideration of the mother and fetus as individual people presents an inherent difficulty in implementing randomised controlled trials in fetal medicine.
Please cite this article as: Morris RK, Chan BC, Kilby MD. Advances in fetal therapy. The Obstetrician & Gynaecologist 2010;12:94–102.